The therapeutic dose ranges of hydrochlorothiazide, chlorthalidone, and bendroflumethiazide monotherapy are stated to be 12.0 to 50.0, 12.0 to 25.0, and 2.5 mg, respectively.19,20 From Figure 3A and 3B, it can be seen that these dose ranges are not equieffective for BP reduction;
for systolic BP the equivalent dose of hydrochlorothiazide 25.0 mg is ≈8.0 mg of chlorthalidone and 1.5 mg of bendroflumethiazide. A common reference source21 states that hydrochlorothiazide and chlorthalidone are equipotent, although in vitro studies suggest that the affinity of chlorthalidone for the NaCl cotransporter is ≈2-fold greater than hydrochlorothiazide and that bendroflumethiazide has a 20-fold greater affinity for the NaCl cotransporter than hydrochlorothiazide.6 In addition, the half-life of chlorthalidone is considerably longer than hydrochlorothiazide.
Το πλήρες κείμενο στο Δεν είναι ορατοί οι σύνδεσμοι (links).
Εγγραφή ή
Είσοδος